Clinical Trial Update: Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab in combination with gemcitabine/cisplatin neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma with high recur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• gemcitabine/cisplatin

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Durvalumab, Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN